B Bready
Overview
Explore the profile of B Bready including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
108
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Royce M, McGarry W, Bready B, Dakhil S, Belt R, Goodwin J, et al.
J Clin Oncol
. 1999 Oct;
17(10):3276-82.
PMID: 10506630
Purpose: Several agents have been evaluated for their effect as biochemical modulators of fluorouracil (5-FU) in the treatment of metastatic colorectal carcinoma. In this study, we used folinic acid (FA),...
2.
Pazdur R, Lassere Y, Bready B, Ho D
Invest New Drugs
. 1997 Jan;
15(2):123-8.
PMID: 9220291
We previously reported results of a Phase II trial of UFT [Taiho Pharmaceutical Ltd., Tokyo, Japan; (BMS-200604) Bristol-Myers Squibb, Princeton, NJ], an oral 4:1 molar concentration of uracil and tegafur,...
3.
Pazdur R, Lassere Y, Bready B, Ho D
Anticancer Drugs
. 1996 Sep;
7(7):728-33.
PMID: 8949982
We conducted two consecutive phase I clinical trials to identify the qualitative and quantitative toxic effects of uracil-tegafur (UFT) [Taiho Pharmaceutical Co. Ltd, Tokyo, Japan; (BMS-200604) Bristol-Myers Squibb, Princeton, NJ]...
4.
Moore Jr D, Pazdur R, Sugarman S, Jones 3rd D, Lippman S, Bready B, et al.
Am J Clin Oncol
. 1995 Dec;
18(6):525-7.
PMID: 8526197
The combination of interferons (IFNs) and retinoids in antineoplastic therapy is based upon preclinical, in vitro, and in vivo observations. Retinoid-IFN combinations have shown significant antitumor activity against advanced cutaneous...
5.
Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma
Pazdur R, Bready B, Ajani J, Abbruzzese J, Markowitz A, Sugarman S, et al.
Am J Clin Oncol
. 1995 Oct;
18(5):436-8.
PMID: 7572763
Phase II trials of the novel biologic combination isotretinoin (13-cis-retinoic aid) plus recombinant interferon alfa-2a have demonstrated this combination's major activity against advanced squamous cell carcinoma of the skin and...
6.
Pazdur R, Lassere Y, Rhodes V, Ajani J, Sugarman S, Patt Y, et al.
J Clin Oncol
. 1994 Nov;
12(11):2296-300.
PMID: 7964943
Purpose: To determine the activity and evaluate the toxicity of uracil and tegafur in a 4:1 molar concentration (UFT; Taiho Pharmaceutical Ltd, Tokyo, Japan) plus oral calcium leucovorin in the...
7.
Pazdur R, Moore D, Bready B, Giannone L, Maldonado A, Lin Y, et al.
Ann Oncol
. 1994 Sep;
5(7):646-8.
PMID: 7527654
Background: The methotrexate analogue edatrexate (10-ethyl-10-deaza-aminopterin, or 10-EDAM) has demonstrated greater activity than methotrexate has against murine tumors and human tumor xenografts. Phase II trials of edatrexate have already demonstrated...
8.
Pazdur R, Lassere Y, Soh L, Ajani J, Bready B, Soo E, et al.
Ann Oncol
. 1994 May;
5(5):468-70.
PMID: 7915537
Background: Docetaxel (Taxotere) is prepared from a noncytotoxic precursor extracted from the needles of the Taxus baccata. Preclinical investigations have demonstrated that docetaxel is very active in colon adenocarcinoma murine...
9.
Moore Jr D, Pazdur R, Abbruzzese J, Ajani J, Dubovsky D, Wade 3rd J, et al.
Ann Oncol
. 1994 Mar;
5(3):286-7.
PMID: 8186177
Background: The methotrexate analogue 10-ethyl-10-deazaaminopterin (10-EdAM, or edatrexate) has shown antitumor activity in preclinical testing and clinical studies of patients with breast, lung and head and neck carcinomas. A phase...
10.
Pazdur R, Bready B, Scalzo A, Brandof J, Close D, Kolbye S, et al.
Invest New Drugs
. 1994 Jan;
12(3):263-5.
PMID: 7896547
Piroxantrone, a synthetic intercalating agent, was studied in patients with advanced, measurable gastric adenocarcinoma who had not received prior chemotherapy. The starting piroxantrone dose was 150 mg/m2 given intravenously over...